v3.26.1
Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 8,315 $ 4,235
Operating expenses:    
Research and development [1] 46,662 42,496
Sales, general, and administrative [1] 12,334 19,068
Depreciation and amortization 6,838 5,331
Total operating expenses 65,834 66,895
Loss from operations (57,519) (62,660)
Other income:    
Interest and other (3,643) (5,523)
Grants and incentives (4,339) (4,153)
Total other income (7,982) (9,676)
Loss before income tax (49,537) (52,984)
Income tax recovery (6,372) (7,363)
Net loss (43,165) (45,621)
Foreign currency translation adjustment 1,815 (2,620)
Comprehensive loss $ (41,350) $ (48,241)
Net loss per share    
Basic (in dollars per share) $ (0.14) $ (0.15)
Diluted (in dollars per share) $ (0.14) $ (0.15)
Weighted-average common shares outstanding    
Basic (in shares) 303,074,605 297,692,663
Diluted (in shares) 303,074,605 297,692,663
Research fees    
Revenue:    
Total revenue $ 8,124 $ 4,068
Licensing and royalty revenue    
Revenue:    
Total revenue $ 191 $ 167
[1] Exclusive of depreciation and amortization